Sentence examples for reduction of infarction from inspiring English sources

The previous Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery I (PRIMO-CABG I) trial (n = 3099) indicated that C5 complement inhibition with pexelizumab might reduce myocardial infarction (MI) and postoperative mortality.

OBJECTIVE: The previous Pexelizumab for Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery I (PRIMO-CABG I) trial (n = 3099) indicated that C5 complement inhibition with pexelizumab might reduce myocardial infarction (MI) and postoperative mortality.

There was synergistic effect observed with the combination of JA and UA with regard to the reduction of infarction volumes, a decrease in the neurological deficit score and the MRI results in ischemic rats (Liu et al., 2012).

It is therefore possible that the E2-mediated reduction of infarction size seen in these models may be caused by anti-inflammatory or anti-apoptotic activities of E2 [44], [44].

In contrast, the DM group did not show any reduction of infarction size under all conditions.

Improvement of neurological function and reduction of infarction gradually decreased with delay of administration of JZQKL.

A significant reduction of infarcted tissue and infarction size was observed with linagliptin administration that was followed by a significant elevation of endogenous GLP-1 plasma concentrations.

Unfortunately, in the last decades only few of the therapeutic interventions effective in the reduction of myocardial infarction and cardiac remodeling in animal models of ischemia, ischemia/reperfusion, and chronic myocardial infarction resulted to be effective also in patients experiencing a real heart attack.

Of note, this finding is in line with the results of the NEXT and COMPARE II trials, 9 10 both of which showed a numerical reduction of myocardial infarction associated with everolimus-ES compared with biodegradable polymer biolimus-ES, which became significant for Q-wave myocardial infarction in the latter.

Extrapulmonary effect of iNO on reduction of myocardial infarction size and improved left ventricular systolic function have been shown in a murine model [30].

But the risk reduction of myocardial infarction, stroke, and heart failure was relatively low [ 1].